These in vivo results suggest that targeting the HSP90-Src-mediated pathway may effectively suppress tumor growth and metastasis of 5-FU resistant colon cancer, providing effective second-line treatment strategies for colon cancer. This evidence concerns the gene SRC and neoplasm.